Status:
COMPLETED
Performance Under SGLT-2-Inhibitors in Humans
Lead Sponsor:
Berner Klinik Montana
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
40+ years
Brief Summary
The PUSH Study is conceived to investigate the early effects of SGLT-2-Inhibitors on the physical performance of patients with Type-II-Diabetes mellitus compared to patients under other therapy regime...
Detailed Description
SGLT-2-Inhibitors have been shown to improve cardiovascular outcomes in patients with type II diabetes mellitus. Present evidence shows this effect to be not directly related to better serum glucose l...
Eligibility Criteria
Inclusion
- informed consent
- ambulatory patients
Exclusion
- relevant limitations in movement
Key Trial Info
Start Date :
January 1 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2020
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT03422263
Start Date
January 1 2018
End Date
September 30 2020
Last Update
October 8 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Berner Klinik Montana
Crans-Montana, Valais, Switzerland, 3963